Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy
Overview
- Phase
- Phase 2
- Intervention
- Ranibizumab
- Conditions
- Diabetic Macular Edema
- Sponsor
- Vitreo-Retinal Associates, PC
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Change in Visual Acuity Scores at Month 12 Compared to Baseline
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This study is designed to confirm that the investigational drug Ranibizumab given by injection into the eye is safe and effective to use in people with diabetic macular edema (DME).
Detailed Description
Ranibizumab works by blocking Vascular Endothelial Growth Factor (VEGF), a substance which is found in eyes with diabetic eye disease and which causes leakage from blood vessels. Several studies have suggested that eyes with DME may have very high levels of VEGF; therefore, Ranibizumab may be helpful in blocking VEGF and decreasing DME. Ranibizumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of wet age-related macular degeneration (AMD) and Retinal Vein Occlusion at the dose amount of 0.5 mg. Ranibizumab has not been approved for use in subjects with DME.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects will be eligible if the following criteria are met:
- •Age \> 18 years
- •Diagnosis of diabetes mellitus (type 1 or 2)
- •Residual edema as determined by mean foveal thickness on Cirrus OCT \> 300 microns and leakage seen on FA at baseline
- •Clinical evidence of retinal thickening due to macular edema involving the center of the macula, associated with diabetic retinopathy.
- •Previous history of at least 4 or more consecutive anti-VEGF intravitreal injections of Pegaptanib sodium or Bevacizumab (consecutive injections administered no more than 6 weeks apart in the last year) for the treatment of diabetic macular edema.
- •Previous history of focal laser and/or intravitreal steroid injection for the treatment of diabetic macular edema.
- •BCVA of 20/32-20/400 (ETDRS)
- •Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria
- •Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception. . The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
- •Participation in another ocular investigation or trial simultaneously.
- •Systemic use of anti-VEGF within 3 months prior to day
- •Previous intravitreal ranibizumab within 3 months prior to day 0
- •Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110)
- •Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse).
- •Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema.
- •An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis, ischemic maculopathy or geographic atrophy).
- •Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gass).
- •Evidence of active neovascularization of the iris or retina.
Arms & Interventions
Arm 1:The PRN Group
You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
Intervention: Ranibizumab
arm 2:The Monthly Group:
You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
Intervention: Ranibizumab
Outcomes
Primary Outcomes
Change in Visual Acuity Scores at Month 12 Compared to Baseline
Time Frame: 12 months
Secondary Outcomes
- Resolution of residual edema compared to baseline as determined by mean foveal thickness on Cirrus OCT 300 microns at Month 6 and Month 12.(12 months)